| Tammy Lyn Yanovitch, MD | |
|
608 Stanton L Young Blvd, Oklahoma City, OK 73104 | |
| (405) 271-6060 | |
| (405) 271-3013 |
| Full Name | Tammy Lyn Yanovitch |
|---|---|
| Gender | Female |
| Speciality | Ophthalmology |
| Experience | 22 Years |
| Location | 608 Stanton L Young Blvd, Oklahoma City, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124057039 | NPI | - | NPPES |
| 200352880A | Medicaid | OK |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dean Mcgee Eye Institute | 3779495353 | 40 |
News Archive
BioClinica, Inc., a global provider of clinical trial management services, today announced that a Top Ten pharmaceutical company has entered into a five-year enterprise-wide agreement for BioClinica Optimizer to simulate and forecast clinical trial supply scenarios for their worldwide clinical trial operations.
Say hello to Botax, the 5% tax on cosmetic procedures that was a surprise addition to the roughly 2,000 page health care reform bill. The proposed tax, scheduled to take effect January 2010, has been suggested as a way to help fund health care reform.
In the battle against cancer, which kills nearly 8 million people worldwide each year, doctors have in their arsenal many powerful weapons, including various forms of chemotherapy and radiation. What they lack, however, is good reconnaissance — a reliable way to obtain real-time data about how well a particular therapy is working for any given patient.
Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) and granted a six-month Priority Review for once-daily Truvada (emtricitabine/tenofovir disoproxil fumarate) for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection among uninfected adults.
University of Minnesota Medical School researchers studied SARS-CoV-2 infections at individual cellular levels and made four major discoveries about the virus, including one that validates the effectiveness of remdesivir - an FDA-approved antiviral drug - as a form of treatment for severe COVID-19 disease.
› Verified 3 days ago
| Entity Name | Dean Mcgee Eye Institute |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245209675 PECOS PAC ID: 3779495353 Enrollment ID: O20031103000297 |
News Archive
BioClinica, Inc., a global provider of clinical trial management services, today announced that a Top Ten pharmaceutical company has entered into a five-year enterprise-wide agreement for BioClinica Optimizer to simulate and forecast clinical trial supply scenarios for their worldwide clinical trial operations.
Say hello to Botax, the 5% tax on cosmetic procedures that was a surprise addition to the roughly 2,000 page health care reform bill. The proposed tax, scheduled to take effect January 2010, has been suggested as a way to help fund health care reform.
In the battle against cancer, which kills nearly 8 million people worldwide each year, doctors have in their arsenal many powerful weapons, including various forms of chemotherapy and radiation. What they lack, however, is good reconnaissance — a reliable way to obtain real-time data about how well a particular therapy is working for any given patient.
Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) and granted a six-month Priority Review for once-daily Truvada (emtricitabine/tenofovir disoproxil fumarate) for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection among uninfected adults.
University of Minnesota Medical School researchers studied SARS-CoV-2 infections at individual cellular levels and made four major discoveries about the virus, including one that validates the effectiveness of remdesivir - an FDA-approved antiviral drug - as a form of treatment for severe COVID-19 disease.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tammy Lyn Yanovitch, MD 608 Stanton L Young Blvd, Oklahoma City, OK 73104-5014 Ph: (405) 271-6060 | Tammy Lyn Yanovitch, MD 608 Stanton L Young Blvd, Oklahoma City, OK 73104 Ph: (405) 271-6060 |
News Archive
BioClinica, Inc., a global provider of clinical trial management services, today announced that a Top Ten pharmaceutical company has entered into a five-year enterprise-wide agreement for BioClinica Optimizer to simulate and forecast clinical trial supply scenarios for their worldwide clinical trial operations.
Say hello to Botax, the 5% tax on cosmetic procedures that was a surprise addition to the roughly 2,000 page health care reform bill. The proposed tax, scheduled to take effect January 2010, has been suggested as a way to help fund health care reform.
In the battle against cancer, which kills nearly 8 million people worldwide each year, doctors have in their arsenal many powerful weapons, including various forms of chemotherapy and radiation. What they lack, however, is good reconnaissance — a reliable way to obtain real-time data about how well a particular therapy is working for any given patient.
Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) and granted a six-month Priority Review for once-daily Truvada (emtricitabine/tenofovir disoproxil fumarate) for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection among uninfected adults.
University of Minnesota Medical School researchers studied SARS-CoV-2 infections at individual cellular levels and made four major discoveries about the virus, including one that validates the effectiveness of remdesivir - an FDA-approved antiviral drug - as a form of treatment for severe COVID-19 disease.
› Verified 3 days ago
Vinay Ashok Shah, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 9821 S May Ave Ste C, Oklahoma City, OK 73159 Phone: 405-691-0505 Fax: 405-691-0507 | |
Cynthia A Bradford, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 608 Stanton L Young Blvd, Oklahoma City, OK 73104 Phone: 405-271-6060 Fax: 405-271-7873 | |
Jila Noorikolouri, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 608 Stanton L Young Blvd, Oklahoma City, OK 73104 Phone: 405-271-6060 Fax: 405-271-3013 | |
Dr. Brian Keith Firestone, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 608 Stanton L Young Blvd, Oklahoma City, OK 73104 Phone: 405-271-6060 Fax: 405-271-7873 | |
David W Parke Ii, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 608 Stanton L Young Blvd, Oklahoma City, OK 73104 Phone: 405-271-1092 | |
Gary Waine Wilson, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 7101 Nw Expressway, Suite 335, Oklahoma City, OK 73132 Phone: 405-722-2020 Fax: 405-516-6126 | |
David W. Jackson, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 608 Stanton L Young Blvd, Oklahoma City, OK 73104 Phone: 405-271-1095 |